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ABSTRACT SUMMARY 
Here we present in situ and in vivo studies in 
rats showing the promise of polymeric 
microcontainers as an oral drug delivery system 
for the poorly water-soluble drug, furosemide. 
The microcontainers showed interaction with 
the intestinal mucus and an increased oral 
bioavailability of furosemide was found when 
dosed in microcontainers compared to the 
powder form.  
 
INTRODUCTION 
Oral delivery of drugs is the preferred 
administration route. For some drugs, it can be 
necessary to employ drug delivery systems e.g. 
to reduce variability in oral bioavailability 
and/or to protect the drug from the harsh 
environment of the stomach [1]. 
Microcontainers are a promising advanced drug 
delivery system.  The size and shape of the 
microcontainers can easily be controlled and 
therefore, polydispersity is avoided as seen for 
e.g. micro- and nanoparticles. Microcontainers 
are polymeric, cylindrical devices in the 
micrometer size range (Fig 1A), and a major 
advantage is that these microcontainers allow 
for unidirectional release, as only one side is 
open. Moreover, the drug can be protected 
inside the cavity of the microcontainer until 
release is desirable e.g. in the small intestine [2]. 
 
         
Fig 1: A) Image of a polymeric microcontainer 
and B) filled with the amorphous sodium salt of 
furosemide 
 
The aim of the current study was to investigate 
interactions between the microcontainers and 
the small intestine in situ and furthermore, to 
evaluate the in vivo performance of the 
microcontainers filled with amorphous sodium 
salt of furosemide (ASSF) after oral dosing to 
rats (Figure 2). 
 
 
Fig 2: Illustration of the experimental set-up 
with drug-filled microcontainers (B), coated 
with a pH-sensitive or mucoadhesive membrane 
(C), and then tested using an intestinal perfusion 
set-up and in a pharmacokinetic study (D).  
 
EXPERIMENTAL METHODS 
 SU-8 microcontainers were produced 
using two steps of photolithography and the 
fabrication resulted in microcontainers with a 
size of 223 µm (Fig 1A). Following the 
fabrication, the microcontainers were filled with 
the ASSF powder (Fig 1B) [3]. Subsequently, 
the drug-filled microcontainers were spray 
coated with a polymeric lid of either the pH-
sensitive polymer, Eudragit® L100 or the 
mucoadhesive polymer, chitosan.   
In situ intestinal perfusion studies were 
performed in rats [4]. The coated and drug-filled 
microcontainers were dosed together with 10 
mL of phosphate buffer, pH 6.5 to the small 
intestine. Furthermore, a solution of furosemide 
in phosphate buffer as well as empty 
microcontainers, were dosed as controls. 200 µL 
A) B)
of sample was withdrawn every 5 min for 30 
min. At the end of the study, the small intestine 
was harvested from the rat and imaged under a 
UV and fluorescence microscope.  
For the in vivo studies, the rats were dosed 
orally with gelatin capsules (size 9) loaded with 
drug-filled microcontainers coated with 
Eudragit® L100. As control, capsules were filled 
with the powder of ASSF followed by coating 
of the capsules with Eudragit® L100. Ten 
samples of 200 µL blood were withdrawn from 
the tail vein during 24 h. 
 
RESULTS AND DISCUSSION 
The microscope images of the small intestine 
after the perfusion studies showed that the 
microcontainers interacted with the mucus in the 
small intestine, and the microcontainers were 
engulfed by the intestinal mucus (Fig 3). By 
these qualitative results, it was observed that 
also without coating, the microcontainers 
interacted with the intestinal mucus (Fig 3C).   
 
 
Fig 3: Microcontainers in intestinal mucus 
following in situ intestinal perfusion studies. 
Microcontainers were filled with ASSF and 
coated with a lid of A) Eudragit® L100 and B) 
chitosan. C) empty microcontainers without 
drug and coating. 
 
The oral bioavailability study showed that the 
relative oral bioavailability of ASSF in 
microcontainers was found to be 220±43% 
when comparing to drug-filled capsules coated 
with Eudragit. This was reflected by a larger 
area under the curve (AUC) for the ASSF in 
microcontainers (Fig 4).   
 
  
Fig 4: Plasma concentrations of microcontainers 
filled with ASSF coated with Eudragit® L100 
and filled into capsules and ASSF dosed in 
capsules with Eudragit coating after orally 
dosing to rats 
 
CONCLUSION 
Microcontainers were shown to interact 
with the intestinal mucus after the in situ 
studies. Furthermore, furosemide confined in 
microcontainers showed a prolonged absorption 
resulting in an oral bioavailability of 220% 
compared to furosemide in a coated capsule. 
The use of microcontainers therefore shows 
considerable potential as a new oral drug 
delivery approach. 
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